Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805323 | 0.81 | PTGDR2 (0.38) | PTGDR2PDE5AEGLN1NR3C1CYP11B2 | |
| SCHEMBL29438003 | 0.81 | PTGDR2 (0.38) | PTGDR2PDE5AEGLN1GPR119NR3C1 | |
| SCHEMBL1978997 | 0.81 | PTGDR2 (0.38) | PTGDR2PDE5AEGLN1GPR119NR3C1 | |
| SCHEMBL18952995 | 0.78 | PTGDR2 (0.38) | PTGDR2EGLN1CYP11B2ELANEHSD11B1 | |
| SCHEMBL18952943 | 0.78 | PTGDR2 (0.37) | PTGDR2PDE5AEGLN1CYP11B2HSD11B1 | |
| SCHEMBL30939616 | 0.76 | HSD11B1 (0.38) | PTGDR2PDE5AEGLN1CYP11B2ELANE | |
| SCHEMBL1979096 | 0.76 | HSD11B1 (0.38) | PTGDR2PDE5AEGLN1CYP11B2ELANE | |
| SCHEMBL25053757 | 0.75 | PTGDR2 (0.39) | PTGDR2EGLN1CYP11B2ELANEPARP1 | |
| SCHEMBL19805308 | 0.75 | SSTR4 (0.32) | AKR1C3 | |
| SCHEMBL19670107 | 0.75 | AR (0.34) | GPR119HRH3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | PTGDR2 1454/4885PDE5A 834/4885EGLN1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.